Uniphar (LON:UPR) Earns “Buy” Rating from Shore Capital

Uniphar (LON:UPRGet Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Shore Capital in a research note issued on Tuesday, Marketbeat reports.

Uniphar Stock Performance

LON UPR opened at GBX 219.10 ($2.78) on Tuesday. Uniphar has a 1-year low of GBX 163 ($2.07) and a 1-year high of GBX 256 ($3.25). The company has a 50 day moving average of GBX 184.78 and a 200-day moving average of GBX 197.39. The company has a current ratio of 0.90, a quick ratio of 0.60 and a debt-to-equity ratio of 119.48. The firm has a market cap of £682.02 million, a price-to-earnings ratio of 15.24 and a beta of 0.75.

About Uniphar

(Get Free Report)

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

Further Reading

Receive News & Ratings for Uniphar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniphar and related companies with MarketBeat.com's FREE daily email newsletter.